What's new at Medix Biochemica

Streamlining Cardiac Marker Assay Development with Medix Biochemica

Written by Medix Biochemica | Oct 1, 2024 9:00:00 AM

Cardiovascular diseases (CVDs) kill an estimated 17.9 million people each year.1 Cardiac biomarkers play a critical role in the diagnosis, monitoring, treatment, prognosis and prediction of many of these diseases.2,3 This article will discuss how, as an end-to-end in vitro diagnostic (IVD) raw materials supplier, Medix Biochemica can help you streamline your development of cardiac marker assays.

 

The Medix Biochemica advantage

Medix Biochemica offers a range of antibodies and antigens for markers commonly used to diagnose CVDs and to monitor patients’ treatment.4

“By enabling clinicians to monitor biomolecules that are released into the blood when the heart is damaged or stressed, IVD assays support diagnosis of conditions including coronary heart disease, cerebrovascular disease, and deep vein thrombosis to guide therapeutic intervention. 

IVD assay performance and utility hinges on high-quality reagents that are available in unlimited supply.”
                                                                                                                                                                                                                               - Medix Biochemica4

What makes Medix Biochemica the IVD industry’s first choice for a raw material partner?5

  • A collaborative, customer-centric approach to development and support
  • Attention to product performance and quality
  • Industry expertise
  • A global footprint
  • Expansive current offerings

We understand the needs of our customers on technical aspects, like product specifications and product range, and on logistical aspects, like supply chain security and speedy response rates – and we conduct ourselves accordingly.

Did you know? According to the World Health Organization, more than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people younger than 70 years old.1

The advantages of consolidating supply through Medix Biochemica

The burden of managing multiple raw-material suppliers is a major challenge for IVD test manufacturers.6 Here’s how partnering with Medix Biochemica can help:

Efficiency gains5

  • Purchasing more volume through fewer suppliers allows for better pricing on raw materials.
  • Fewer points of contact minimize risk and simplify the supplier management and ordering processes.
  • This leads to a more collaborative supplier relationship, plus increased visibility and control.

Cost savings5

  • Fewer, larger shipments are more cost-effective and have a lower environmental impact.
  • Fewer suppliers means a reduction in order processing costs.

  • An end-to-end supplier allows for more visibility into – and control over – change notifications, which can otherwise be costly.

Quality assurance5

  • ISO certifications minimize compliance risk for IVD manufacturers. Medix Biochemica is willing to support customers during audits.
  • Our stringent quality assurance (QA) processes effectively manage your supply chain risks and concerns.
  • Strong QA processes mean we deliver lot-to-lot consistency and reliable product performance.
Did you know? About one in 20 adults aged 20 and older have coronary artery disease (CAD), the most common type of heart disease.7

 

Strategic consolidation: The Creative Laboratory Products acquisition story5,8

In 2016, Burton Lee, then CEO of Lee Biosolutions (now part of Medix Biochemica), acknowledged the benefits of supplier consolidation.

That same year, Lee Biosolutions acquired the entire product line of Creative Laboratory Products, Inc., a US-based producer of human and animal cholesterol concentrates. The acquisition went smoothly due to the strong relationship between the two companies, and most Creative Laboratory Products' staff relocated to St. Louis, Missouri, to join the larger Lee Biosolutions team.

This acquisition ensured a consistent, high-quality, long-term supply (and increased scale) of critical raw materials for cardiovascular IVD testing, including:

  • bovine and human high-density lipoprotein (HDL); 
  • low-density lipoprotein (LDL) cholesterol concentrate; and 
  • delipidized serum.

This strategic move marked an early step in Medix Biochemica’s ongoing efforts to ensure supply security, product offerings and global footprint, aiming to become the top choice as a raw material supplier in the IVD industry. Read more about the acquisition.

Did you know? A high plasma concentration of LDL cholesterol is a crucial risk factor for atherosclerotic cardiovascular disease (ACD).2

Why choose Medix Biochemica?5

  • Our comprehensive product offerings mean we have what our customers need, when they need it.
  • Our legacy of high-performing, high-quality products offer lot-to-lot consistency, reliable performance, and less need to pre-qualify new lots prior to acceptance or to re-order under-performing materials.
  • Expertise in the industry means we understand the needs and pain points of our customers and operate accordingly, developing products and providing technical and customer support.
  • Our customer-focused approach leads to transparent, collaborative and timely communication.

Do you want to discuss the IVD materials you need with an expert end-to-end supplier? Contact our dedicated sales team to find out how we can help you.

References: 

  1. Cardiovascular diseases. WHO. Accessed August 18, 2024. https://www.who.int/health-topics/cardiovascular-diseases.
  2. Thupakula S, Nimmala SSR, Ravula H, et al. Emerging biomarkers for the detection of cardiovascular diseases. Egypt Heart J. 2022;74(1):77. doi:10.1186/s43044-022-00317-2.
  3. Cardiac enzymes (cardiac biomarkers). Cleveland Clinic. Accessed August 16, 2024. https://my.clevelandclinic.org/health/articles/22115-cardiac-enzymes-cardiac-biomarkers.
  4. Cardiac marker reagents. Medix Biochemica. Accessed August 18, 2024. https://www.medixbiochemica.com/cardiac-marker-reagents.
  5. Expert opinion. Anthony Austin, Global Marketing Manager, Medix Biochemica. July 2024.
  6. Expert opinion. Anthony Austin, Global Marketing Manager, Medix Biochemica. April 2024.
  7. Heart disease facts. CDC. Accessed August 16, 2024. https://www.cdc.gov/heart-disease/data-research/facts-stats/index.html.
  8. Lee Biosolutions purchases Creative Laboratory Products. Lee Biosolutions. Accessed August 18, 2024. https://www.leebio.com/blog/148/lee-biosolutions-inc-purchases-creative-laboratory-products-product-line.
View full post